Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
11/30/2016 12/01/2016 12/02/2016 12/05/2016 12/06/2016 Date
70.25(c) 68.85(c) 68.75(c) 69.5(c) 69.55 Last
6 215 135 8 441 223 5 973 475 4 760 576 964 707 Volume
+0.29% -1.99% -0.15% +1.09% +0.07% Change
More quotes
Financials ($)
Sales 2016 48 805 M
EBIT 2016 11 857 M
Net income 2016 8 046 M
Debt 2016 15 084 M
Yield 2016 4,09%
Sales 2017 49 494 M
EBIT 2017 12 147 M
Net income 2017 8 567 M
Debt 2017 13 707 M
Yield 2017 4,28%
P/E ratio 2016 20,02
P/E ratio 2017 18,83
EV / Sales2016 4,01x
EV / Sales2017 3,93x
Capitalization 180 598 M
More Financials
Company
Novartis AG develops, manufactures, and markets healthcare products.It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, and Corporate Activities.The Pharmaceuticals segment provides patent-protected prescription medicines.The Alcon segment offers surgical, ophthalmic... 
Sector
Pharmaceuticals
Calendar
12/05 | 03:00amPresentation
More about the company
Surperformance© ratings of Novartis AG
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS AG
09:46a NOVARTIS : announces Zykadia® first-line study results showing 16.6 month progre..
12/05 Une offre de Novartis sur Actelion jugée peu probable
12/05 NOVARTIS : data shows Treatment-free Remission rates are consistently above 50% ..
12/05 NOVARTIS : survey uncovers real-world burden of myeloproliferative neoplasms (ra..
12/05 NOVARTIS : Selexys exit validates Oklahoma as place to start biotech firms
12/05 NOVARTIS : SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequenc..
12/05 OXFORD BIOMEDICA : Notes Positive Novartis CTL019 Findings
12/05 NOVARTIS : SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequenc..
12/05 NOVARTIS : plays down bid for biotech giant
12/05 NOVARTIS : New interim data demonstrate Sandoz proposed biosimilar rituximab has..
More news
Sector news : Pharmaceuticals - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on NOVARTIS AG 
10/24A trend reversal can be anticipated
More Strategies
News from SeekingAlpha
12/05 Novartis Makes Its Case For Driving A CAR Into The Real World
12/05 BIOTECH FORUM DAILY DIGEST : Biotech Has Tough Week; Will Conference Buoy Immuno..
12/05 Avillion's BOSULIF beats Gleevec in late-stage study in type of leukemia; lic..
12/05 WALL STREET BREAKFAST : Investors Shrug Off Italy's Referendum Result
12/05 Novartis softens prospects for Actelion bid
Advertisement
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 83,3 $
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-20.79%180 598
JOHNSON & JOHNSON8.98%304 536
PFIZER INC.-2.14%191 699
ROCHE HOLDING LTD.-19.65%189 885
MERCK & CO., INC.15.73%166 118
SANOFI-4.20%105 342
More Results